Skip to main content

Swell’s BBB- Rating Reaffirmed by HR Ratings for a Second Consecutive Year, with a Stable Outlook

Ethel Mora, CEO of Swell.Ethel Mora, CEO of Swell, the Mexican non-bank financial institution whose BBB- rating was reaffirmed by HR Ratings for a second consecutive year.MEXICO CITY, June 18, 2026.- Swell, a leading Mexican credit provider, has had its BBB- rating reaffirmed with a Stable Outlook by HR Ratings for a second consecutive year. HR Ratings announced the decision on June 17, 2026. Swell is a Mexican non-bank financial institution focused on financing small and medium-sized enterprises (SMEs). The agency also affirmed Swell’s HR3 short-term rating, citing improvements in capitalization, profitability, financial efficiency, and funding diversification, and a capitalization ratio of 37.9%, supported by earnings generation and operational efficiencies. It also cited a 3.4% return on assets (ROA), tied to a wider...

Continue reading

SkiStar AB Interim Report September 2025-May 2026

STABLE DEVELOPMENT IN UNCERTAIN TIMES Third QuarterNet sales amounted to SEK 1,441 million (1,375), an increase of SEK 66 million, 5 percent. Operating profit amounted to SEK 347 million (377), a decrease of SEK 30 million, 8 percent. Operating profit adjusted for capital gains from exploitation assets amounted to SEK 346 million (347), a decrease of SEK 1 million, 0 percent. Capital gains from exploitation assets were included with SEK 1 million (30). Cash flow from operating activities amounted to SEK -368 million (-460), an increase of SEK 92 million. Basic and diluted earnings per share amounted to SEK 3.43 (3.82), a decrease of 10 percent.First Nine MonthsNet sales amounted to SEK 4,663 million (4,348), an increase of SEK 315 million, 7 percent. Operating profit amounted to SEK 1,146 million (1,095), an increase of SEK 51 million,...

Continue reading

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the first quarter ended March 31, 2026 and highlighted progress across its clinical and preclinical portfolio. “During...

Continue reading

Safe Bulkers, Inc. Reports First Quarter 2026 Results and Declares Dividend on Common Stock

MONACO, June 17, 2026 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the “Company”) (NYSE/Euronext Athens: SB), an international provider of marine drybulk transportation services, announced today its unaudited financial results for the three-month period ended March 31, 2026. The Board of Directors (the “Board”) of the Company also declared a cash dividend of $0.06 per share of outstanding common stock.         Financial highlights        In million U.S. Dollars except per share data Q1 2026 Q42025 Q3 2025 Q22025 Q12025Net revenues 74.4 72.6 73.1 65.7 64.3Net income 22.2 11.8 17.8 1.7 7.2Adjusted Net income1 20.7 15.9 13.9 3.0 7.8EBITDA2 42.2 33.3 40.1 24.2 28.8Adjusted EBITDA 2 40.7 37.4 36.1 25.5 29.4Earnings per share basic and diluted3 0.20 0.10 0.15 0.00 0.05Adjusted Earnings...

Continue reading

Admaxxer Surpasses 12,000 Active Brands and $3 Billion in Tracked GMV, Cementing Its Position as the Leading Triple Whale Alternative for DTC Shopify Analytics

Admaxxer reported four operating milestones — 12,000 active direct-to-consumer brands, $3 billion in cumulative tracked gross merchandise value, a 93% Conversions API match rate, and the launch of a reconciled multi-touch attribution model alongside an eleven-tool Model Context Protocol server — as the platform positions itself as the leading Triple Whale alternative for Shopify and other e-commerce brands. New York, NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Admaxxer, a direct-to-consumer (DTC) analytics and AI ad-operations platform for Shopify and other e-commerce brands, today reported four operating milestones, measured as of May 31, 2026, and reinforced its positioning as the leading Triple Whale alternative for DTC Shopify analytics, per the company’s platform metrics update (published at https://admaxxer.com/methodology):12,000...

Continue reading

VINCI Autoroutes and VINCI Airports traffic in May 2026

   Nanterre, 17 June 2026 VINCI Autoroutes and VINCI Airports traffic in May 2026 I-      Change in VINCI Autoroutes’ intercity networks traffic  May YTD at the end of May (5 months)  % change 2026/2025 % change 2026/2025VINCI Autoroutes +0.3% -1.8%Light vehicles +0.8% -2.2%Heavy vehicles -2.7% +0.5%In May, light vehicle traffic posted a slight increase. It benefited from a favourable calendar effect*, whilst continuing to be hampered by the sharp rise in fuel prices, particularly diesel. On the other hand, heavy vehicle traffic declined, impacted by two fewer working days compared with May 2025.Overall, the decline in traffic since the start of the year has narrowed to -1.8% (compared with -2.5% at the end of April). *positioning of the Ascension weekend (in May this year, in May–June last year) and the Pentecost...

Continue reading

Progressive Reports May 2026 Results

MAYFIELD VILLAGE, OHIO, June 17, 2026 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended May 31, 2026:  May  (millions, except per share amounts and ratios; unaudited) 2026   2025   Change  Net premiums written $ 7,027   $ 6,634   6   %  Net premiums earned $ 7,361   $ 6,715   10   %  Net income $ 1,445   $ 1,065   36   %  Per share available to common shareholders $ 2.47   $ 1.81   36   %  Total pretax net realized gains (losses) on securities $ 215   $ 211   2   %  Combined ratio   82.1     86.9   (4.8 ) pts.  Average diluted equivalent common shares   584.2     587.7   (1 ) %                         May 31,  (thousands; unaudited) 2026   2025   % Change  Policies in Force            Personal Lines            Agency...

Continue reading

17 Education & Technology Group Inc. Announces First Quarter 2026 Unaudited Financial Results

BEIJING, June 17, 2026 (GLOBE NEWSWIRE) — 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading AI-powered application service provider focused on personalized learning solutions, today announced its unaudited financial results for the first quarter of 2026. First Quarter 2026 Highlights1Net revenues were RMB99.5 million (US$14.4 million), compared with net revenues of RMB21.7 million in the first quarter of 2025. Gross margin was 61.9%, compared with 36.2% in the first quarter of 2025. Net loss was RMB19.4 million (US$2.8 million), compared with net loss of RMB30.9 million in the first quarter of 2025. Net loss as a percentage of net revenues was negative 19.5% in the first quarter of 2026, compared with negative 142.8% in the first quarter of 2025. Adjusted net loss2 (non-GAAP), which...

Continue reading

Andrew Peller Limited Reports Financial Results for Fourth Quarter and Fiscal Year 2026

GRIMSBY, Ontario, June 16, 2026 (GLOBE NEWSWIRE) — Andrew Peller Limited (TSX: ADW.A / ADW.B) (“APL” or the “Company”) announced today results for the three and 12 months ended March 31, 2026. All amounts are expressed in Canadian dollars unless otherwise stated. FOURTH QUARTER 2026 HIGHLIGHTSRevenue was $79.5 million, up from $75.5 million in Q4 2025; Gross margin of 52.2%, compared with 52.6% in the prior year; EBITA increased to $15.1 million from $13.5 million in Q4 2025; and Net earnings were $5.7 million ($0.14 per Class A Share), compared to a loss of $0.7 million (loss of $0.02 per Class A Share) in Q4 2025.FISCAL 2026 HIGHLIGHTSRevenue was $393.0 million, up 0.9% from $389.6 million in the prior year; Gross margin of 45.1%, up from 42.8% in the prior year; EBITA grew by 14.7% to $72.1 million, from $62.9 million...

Continue reading

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets  – Company publishes Q1 2026 financial results with revenue in line with prior guidance & substantial year-on-year gross margin percentage improvements              DUBLIN, June 16, 2026 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received additional purchase orders for over 2 million units of its flagship rapid HIV test, TrinScreen™ HIV. These orders are scheduled for fulfillment in Q3 2026 and are expected to make a meaningful contribution to the Company’s 2026 revenue and profitability objectives. These orders provide further...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.